drugset / Trial / NCT07071623
A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)
RandomizedParallel-groupQuadruple-blindPrevention
Summary
Researchers are looking for new medicines to prevent HIV-1 (Human Immunodeficiency Virus Type 1) infection. The goals of this study are to learn: * If taking MK-8527 once a month works to prevent HIV-1 infection better than a standard (usual) pre-exposure prophylaxis (PrEP) taken once a day * About the safety of MK-8527 and if people tolerate it
Timeline
- Start
- 2025-11-10
- Primary completion
- 2027-10-18
- Completion
- 2027-10-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Emtricitabine/tenofovir disoproxil | Unknown | 200 mg | Oral |
| Comparator | Emtricitabine/tenofovir disoproxil | Unknown | 245 mg | Oral |
| Subject | MK-8527 | Small molecule | 11 mg | Oral |